K-ras role in lung cancer therapy

Minerva Chirurgica

Volumn 66, Issue 3, 2011, Pages 251-268

  Zhang, Z ^a   Wang, Zhou ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Genes; Lung neoplasms; Neoplasms; Ras; Second primary; Therapy

Indexed keywords

RAS PROTEIN;

ARTICLE; DRUG EFFECT; GENETICS; HUMAN; LUNG TUMOR; MOLECULARLY TARGETED THERAPY; ONCOGENE RAS; PHYSIOLOGY;

GENES, RAS; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; RAS PROTEINS;

EID: 79961094849     PISSN: 00264733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (99)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer Statistics. CA CANCER J CLIN 2011;61:69-90.
2. Kwiatkowski DJ, Harpole DH Jr, Godleski J, Herndon JE 2nd, Shieh DB, Richards W et al. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. J Clin Oncol 1998;16:2468-77. (Pubitemid 28309043)
3. Omerovic J, Hammond DE, Clague MJ, Prior IA. Ras isoform abundance and signalling in human cancer cell lines. Oncogene 2008;27:2754-62. (Pubitemid 351581461)
4. Minamoto T, Mai M, Ronai Z. K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers - a review. Cancer Detect Prev 2000;24:1-12. (Pubitemid 30152735)
5. Rodenhuis S, Boerrigter L, Top B, Slebos RJ, Mooi WJ, van't Veer L et al. Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. J Clin Oncol 1997;15:285-91. (Pubitemid 27020585)
6. Ramirez JL, Sarries C, de Castro PL, Roig B, Queralt C, Escuin D et al. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Lett 2003, 193:207-16. (Pubitemid 36428904)
7. Patek CE, Arends MJ, Wallace WA, Luo F, Hagan S, Brovvnstein DG et al. Mutationally activated K-ras 4A and 4B both mediate lung carcinogenesis. Exp Cell Res 2008;10; 314:1105-14.
8. Lopez-Alcalá C, Alvarez-Moya B, Villalonga P, Calvo M, Bachs O, Agell N. Identification of essential interacting elements in K-Ras/calmodulin binding and its role in K-Ras localization. J Biol Chem 2008;283:10621-31.
9. Pai FF, Kabsch W, Krengel U, Holmes KC, John J, Wittinghofer A. Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene product p21 in the triphosphate conformation. Nature 1989:341:209-14. (Pubitemid 19231720)
10. Margarit SM, Sondermann H, Hall BE, Nagar B, Hoelz A, Pirruccello M et al. Structural evidence for feedback activation by Ras. GTP of the Ras-specific nucleotide exchange factor SOS. Cell 2003;112:685-95. (Pubitemid 36331780)
11. Hongyo T, Buzard GS, Palli D, Weghorst CM, Amorosi A, Galli M et al. Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high incidence region around Florence, Italy. Cancer Res 1995:55:2665-72.
12. Tsukuda K, Tanino M, Soga H, Shimizu N, Shimizu K. A novel activating mutation of the K-ras gene in human primary colon adenocarcinoma. Biochem Biophys Res Commun 2000;278:653-8.
13. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001;93:1062-74. (Pubitemid 32717538)
14. Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ et al. K-and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 1997;272:14459-64. (Pubitemid 27232866)
15. Mouri W, Tachibana K, Tomiyama A, Sunayama J, Sato A, Sakurada K et al. Downregulation of Ras C-terminal processing by JNK inhibition. Biochem Biophys Res Commun 2008;371:273-7.
16. Trueblood CE, Boyartchuk VL, Picologlou EA, Rozema D, Poulter CD, Rine J. The CaaX proteases, Afclp and Rcelp, have overlapping but distinct substrate specificities. Mol Cell Biol 2000;20:4381-92. (Pubitemid 30346632)
17. Inder KL, Lau C, Loo D, Chaudhary N, Goodall A, Martin S et al. Nucleophosmin and nucleolin regulate K-Ras plasma membrane interactions and MAPK signal transduction. J Biol Chem 2009;284:28410-9.
18. Resh MD. Membrane targeting of lipid modified signal transduction proteins. Sub-cell Biochem 2004;37:217-32.
19. Abankwa D, Gorfe AA, Inder K, Hancock JF. Ras membrane orientation and nanodomain localization generate isoform diversity. Proc Natl Acad Sci USA 2010;107:1130-5.
20. Ganti AK. Epidermal growth factor receptor signaling in nonsmall cell lung cancer. Cancer Invest 2010;28:515-25.
21. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995;80:179-85.
22. Gazin C, Wajapeyee N, Gobeil S, Virbasius CM, Green MR. An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 2007;449:1073-7. (Pubitemid 350014604)
23. Adler V, Pincus MR, Polotskaya A, Montano X, Friedman FK, Ronai Z. Activation of c-Jun-NH2-kinase by UV irradiation is dependent on p21ras. J Biol Chem 1996;271:23304-9. (Pubitemid 26314773)
24. Young A, Lyons J, Miller AL, Phan VT, Alarcón IR, Mc-Cormick F. Ras signaling and therapies. Adv Cancer Res 2009;102:1-17.
25. Gille H, Downward J. Multiple ras effector pathways contribute to G (l) cell cycle progression. J Biol Chem 1999;274:22033-40.
26. Oktay M, Wary KK, Dans M, Birge RB, Giancotti FG. Integrin-mediated activation of focal adhesion kinase is required for signaling to Jun. NH2-terminal kinase and progression through the Gl phase of the cell cycle. J Cell Biol 1999;145:1461-9. (Pubitemid 29310003)
27. Chen Q, Lin TH, der CJ, Juliano RL. Integrin-mediated activation of MEK and mitogen-activated protein kinase is independent of Ras. J Biol Chem 1996;271:18122-7.
28. Clark EA, Hynes RO. Ras activation is necessary for integrin-mediated activation of extracellular signalregulated kinase 2 and cytosolic phospholipase A2 but not for cytoskeletal organization. J Biol Chem 1996;271:14814-8. (Pubitemid 26194962)
29. Howe AK, Juliano RL. Distinct mechanisms mediate the initial and sustained phases of integrin-mediated activation of the Raf/MEK/mitogen- activated protein kinase cascade. J Biol Chem 1998;273:27268-74. (Pubitemid 28500439)
30. Keely PJ, Rusyn EV, Cox AD, Parise LV. R-Ras signals through specific integrin alpha cytoplasmic domains to promote migration and invasion of breast epithelial cells. J Cell Biol 1999;145:1077-88. (Pubitemid 29270064)
31. Singh A, Settleman J. Oncogenic K-ras "addiction" and synthetic lethality. Cell Cycle 2009;8:2676-7.
32. Zabrenetzky V, Harris CC, Steeg PS, Roberts DD. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int J Cancer 1994;59:191-5. (Pubitemid 24343361)
33. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995;55:4575-80.
34. Karreth FA, Tuveson DA. Modelling oncogenic Ras/Raf signalling in the mouse. Curr Opin Genet Dev 2009;19:4-11.
35. Cantrell DA. GTPases and T cell activation. Immunol Rev 2003;192:122-30. (Pubitemid 36613328)
36. Heldin CH. Dimerization of cell surface receptors in signal transduction. Cell 1995;80:213-23.
37. Schlessinger J. Cell Signaling by receptor tyrosine kinases. Cell 2000;103:211-25.
38. Quilliam LA, Huff SY, Rabun PCM, Wei W, Park W, Broek D et al. Membrane-targeting potentiates guanine nucleotide exchange factor CDC25 and SOS1 activation of Ras transforming activity. Proc Natl Acad Sci U. S. A. 1994;91:8512-6. (Pubitemid 24273694)
39. Sondermann H, Soisson SM, Boykevisch S, Yang SS, BarSagi D, Kuriyan J. Structural analysis of autoinhibition in the Ras activator Son of sevenless. Cell 2004;119:393-405. (Pubitemid 39423841)
40. Bernards A, Settleman J. GAP control: regulating the regulators of small GTPases. Trends Cell Biol 2004;14:377-85. (Pubitemid 38891707)
41. Reynolds RM, Browning GG, Nawroz I, Campbell W. Von Recklinghausen's neurofibromatosis: neurofibromatosis type 1. Lancet 2003, 361:1552-4. (Pubitemid 36566351)
42. Gay B, Suarez S, Caravatti G, Furet P, Meyer T, Schoepfer J. Selective GRB2 SH2 inhibitors as anti-Ras therapy. Int J Cancer 1999;83:235-41. (Pubitemid 29449103)
43. Eisenberg S, Giehl K, Henis YI, Ehrlich M. Differential interference of chlorpromazine with the membrane interactions of oncogenic K-Ras and its effects on cell growth. J Biol Chem 2008;283:27279-88.
44. Diaz-Meco MT, Lozano J, Municio MM, Berra E, Frutos S, Sanz L et al. Evidence for the in vitro and in vivo interaction of Ras with protein kinase C zeta. J Biol Chem 1994;269:31706-10. (Pubitemid 24379538)
45. Mizuarai S, Irie H, Schmatz DM, Kotani H. Integrated genomic and pharmacological approaches to identify synthetic lethal genes as cancer therapeutic targets. Curr Mol Med 2008;8:774-83.
46. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9. (Pubitemid 19213607)
47. Bollag G, McCormick F. Differential regulation of ras-GAP and neurofibromatosis gene product activities. Nature 1991;351:576-9. (Pubitemid 21896644)
48. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999;400:464-8. (Pubitemid 29361801)
49. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001;410:1111-6. (Pubitemid 32391044)
50. Fisher GH, Wellen SL, Klimstra D, Lenczowski JM, Tichelaar JW, Lizak MJ et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 2001;15:3249-62. (Pubitemid 34008191)
51. Meuwissen R, Linn SC, van der Valk M, Mooi WJ, Berns A. Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene. Oncogene 2001;20. 6551-8. (Pubitemid 32980281)
52. Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005;92:131-9 (Pubitemid 40188446)
53. Lowy DR, Willumsen BM. Function and regulation of ras. Annu Rev Biochem 1993, 62:851-91. (Pubitemid 23237890)
54. Rossi A, Galetta D, Gridelli C. Biological prognostic and predictive factors in lung cancer. Oncology 2009;77(Suppl 1). 90-6.
55. Suzuki Y, Orita M, Shiraishi M, Hayashi K, Sekiya T. Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1990, 5. 1037-43.
56. Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer 2008;99:923-9.
57. Stacey DW. Cyclin Dl serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol 2003;15:158-63. (Pubitemid 36332190)
58. Downward J. PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 2004;15:177-82. (Pubitemid 38251646)
59. Cary LA, Han DC, Guan JL. Integrin-mediated signal transduction pathways. Histol Histopathol 1999;14:1001-9. (Pubitemid 29320363)
60. Kranenburg O, Gebbink MF, Voest EE. Stimulation of angiogenesis by Ras proteins. Biochim Biophys Acta 2004;1654:23-37. (Pubitemid 38230929)
61. Lee S, Kang J, Cho M, Seo E, Choi H, Kim E etal. Profiling of transcripts and proteins modulated by K-ras oncogene in the lung tissues of K-ras transgenic mice by omics approaches. Int J Oncol 2009;34:161-72.
62. Shih C, Padhy LC, Murray M, Weinberg RA. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 1981;290:261-4. (Pubitemid 11149660)
63. Vitale-Cross, Amornphimoltham P, Fisher G, Molinolo AA, Gutkind JS. Conditional expression of K-ras in an epithelial compartment that includes the stem cells is sufficient to promote squamous cell carcinogenesis. Cancer Res 2004;64:8804-7. (Pubitemid 39665480)
64. Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S et al. Endogenous oncogenic K-ras (G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 2004;5:375-7.
65. Odze RD, Brien T, Brown CA, Hartman CJ, Wellman A, Fogt F. Molecular alterations in chronic ulcerative colitis-associated and sporadic hyperplastic polyps: a comparative analysis. Am J Gastroenterol 2002;97:1235-42. (Pubitemid 34478128)
66. Inder KL, Lau C, Loo D, Chaudhary N, Goodall A, Martin S et al. Nucleophosmin and nucleolin regulate K-Ras plasma membrane interactions and MAPK signal transduction. J Biol Chem 2009;284:28410-9.
67. Arvanitakis M, Van Laethem JL, Parma J, Maertelaer De V, Delhaye M, Deviere J. Predictive factors for pancreatic cancer in patients with chronic pancreatitis in association with K-ras gene mutation. Endoscopy 2004;36. 535-42. (Pubitemid 38811623)
68. Parsons BL, Meng F. K-RAS mutation in the screening, prognosis and treatment of cancer. Biomark Med 2009;3:757-69.
69. Clanton DJ, Hattori S, Shih TY. Mutations of the ras gene product p21 that abolish guanine nucleotide binding. Proc Natl Acad Sci U. S. A. 1986;83:5076-80. (Pubitemid 16051319)
70. Senmaru N, Shichinohe T, Takeuchi M, Miyamoto M, Sazawa A, Ogiso Y et al. Suppression of Erk activation and in vivo growth in esophageal cancer cells by the dominant negative Ras mutant, N116Y. Int J Cancer 1998;7:8366-71.
71. Takeuchi M, Shichinohe T, Senmaru N, Miyamoto M, Fujita H, Takimoto M et al. The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice. Gene Ther 2000;7:518-26. (Pubitemid 30156567)
72. Bossu P, Vanoni M, Wanke V, Cesaroni MP, Tropea F, Melillo G et al. A dominant negative RAS-specific guanine nucleotide exchange factor reverses neoplastic phenotype in K-ras transformed mouse fibroblasts. Oncogene 2000;19:2147-54. (Pubitemid 30251380)
73. Jansen B, Zangemeister-Wittke U. Antisense therapy for cancer - the time of truth. Lancet Oncol 2002;3:672-83. (Pubitemid 35314910)
74. Gray GD, Hernandez OM, Hebel D, Root M, Pow-Sang JM, Wick-strom E. Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice. Cancer Res 1993;53:577-80. (Pubitemid 23059439)
75. Jasinski P, Zwolak P, Terai K, Dudek AZ. Novel Ras pathway inhibitor induces apoptosis and growth inhibition of K-ras-mutated cancer cells in vitro and in vivo. Transl Res 2008;152:203-12.
76. Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 2002;1:347-55.
77. Duursma AM, Agami R. Ras interference as cancer therapy. Semin Cancer Biol 2003;13:267-73. (Pubitemid 38160918)
78. Napoli C, Lemieux C, Jorgensen R. Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co Suppression of Homologous Genes in trans. Plant Cell 1990;2:279-89. (Pubitemid 120029588)
79. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004;432:173-8. (Pubitemid 39545841)
80. Choudhury A, Charo J, Parapuram SK, Hunt RC, Hunt DM, Seliger B et al. Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer 2004;108:71-7. (Pubitemid 37444446)
81. Xia H, Mao Q, Paulson HL, Davidson, BL. siRNA mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002;20:1006-10.
82. Zhiping Zhang, Guanchao Jiang, Fan Yang, Jun. Wang. Knockdown of Mutant K-ras expression by adenovirus-mediated siRNA inhibits the in vitro and in vivo growth of lung cancer cells. Cancer Biology Therapy 2006;5:1481-6.
83. Glomset JA, Farnsworth CC. Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes. Annu Rev Cell Biol 1994;10. 181-205. (Pubitemid 24372820)
84. Liu M, Sjogren AK, Karlsson C, Ibrahim MX, Andersson KM, Olofsson FJ et al. Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer. Proc Natl Acad Sci USA. 2010;107:6471-6.
85. Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Gra-ham SL et al. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 1993;260:1934-7. (Pubitemid 23258273)
86. Haigis KM, Sweet-Cordero A. New insights into oncogenic stress. Nat Genet 2011;43:177-8.
87. Cortes JE, Albitar M, Thomas D, Giles F, Kurzrock R, Thibault A et al. Efficacy of the farnesyl transferase inhibitor, Rl 15777, in chronic myeloid leukemia and other hematological malignancies. Blood 2003;101:1692-7. (Pubitemid 36237561)
88. Haluska P, Dy GK, Adjei AA. Farnesyl transferase inhibitors as anticancer agents. Eur J Cancer 2002;38:1685-700.
89. Wakamatsu N, Collins JB, Parker JS, Tessema M, Clayton NP, Ton TV et al. Gene expression studies demonstrate that the K-ras/Erk MAP kinase signal transduction pathway and other novel pathways contribute to the pathogenesis of cumene-induced lung tumors. Toxicol Pathol 2008;36:743-52.
90. Sun J, Qian Y, Hamilton AD, Sebti SM. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 1998;16:1467-73. (Pubitemid 28151853)
91. Lobell RB, Liu D, Buser CA, Davide JP, DePuy E, Hamilton K et al. Preclinical and clinical pharmacodynamic assessment of L-778, 123, a dual inhibitor of farnesyl.proteintransferaseandgeranylgeranyLprotein transferase type-I. Mol Cancer Ther 2002;1:747-58.
92. Britten CD, Rowinsky EK, Soignet S, Patnaik A, Yao SL, Deutsch P et al. A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778, 123 in patients with solid malignancies. Clin Cancer Res 2001;7:3894-903. (Pubitemid 34044606)
93. Bergo MO, Ambroziak P, Gregory C, George A, Otto JC, Kim E et al. Absence of the CAAX endoprotease Reel: effects on cell growth and transformation. Mol Cell Biol 2002;22:171-81. (Pubitemid 33144266)
94. Puyol M, Martin A, Dubus P, Mulero F, Pizcueta P, Khan G et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010;18. 63-73.
95. Winter-Vann AM, Baron RA, Wong W, Cruz J, York JD, Gooden DM et al. A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells. Proc Natl Acad Sci U. S. A. 2005;102:4336-41. (Pubitemid 40397112)
96. Fossum B, Olsen AC, Thorsby E, Gaudernack G. CD8+ T cells from a patient with colon carcinoma, specific for a mutant p21-Ras-derived peptide (Gly-13YAsp), are cytotoxic towards a carcinoma cell line harbouring the same mutation. Cancer Immunol Immunother 1995;40:165-72.
97. Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, Soreide O et al. Intradermal ras peptide vaccination with granulocyte-macrophage colonystimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 2001;92:441-50. (Pubitemid 32249724)
98. Lu Y, Bellgrau D, Dwyer-Nield LD, Malkinson AM, Duke RC, Rodell TC et al. Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. Cancer Res 2004;64:5084-8. (Pubitemid 39006523)
99. Iincus MR. Development of new anti-cancer peptides from conformational energy analysis of the oncogenic ras-p21 protein and its complexes with target proteins. Front Biosci 2004;9:3486-509.